Oklahoma's bioscience story takes national stagePublished: Wednesday, August 29, 2018 By: Chamber Staff Source: The POINT!
Scientists, business leaders, educators and economic development officers from across the state of Oklahoma took the best of Oklahoma bioscience to Boston to garner interest in one of Oklahoma’s fastest-growing economic sectors. At the 2018 BIO International Convention, the Oklahoma Bioscience Association- and Chamber-led delegation promoted the accomplishments of the Oklahoma bioscience sector and met with potential business partners.
“Oklahoma is fast becoming a breeding ground for the bioscience industry,” said Roy H. Williams, CCE, president and CEO of the Greater Oklahoma City Chamber. “There is groundbreaking research being conducted in Oklahoma City and, alongside the opportunities for collaboration and investment, our bioscience community stands head and shoulders above many locations across the nation.”
Members of the delegation hosted 250 meetings with prospective business partners at the OKBio booth. They were also able to share some of Oklahoma’s recent bioscience success stories. Read on for a recap of how companies are advancing bioscience research in the region.
Oklahoma Medical Research Foundation
Scientists at OMRF have discovered a way in which cells duplicate themselves accurately and completely. The new findings provide a better understanding of how cells replicate, and it could help outline how and why this process goes wrong in cancer.
Moleculera Labs, Inc., an autoimmune neurobiology company, issued a key patent covering the company’s Cunningham Panel™ and its use in helping physicians identify whether an individual’s neurologic and/or psychiatric symptoms could be caused by an autoimmune dysfunction. Specifically, the new patent covers methods of diagnosing Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococci infection (PANDAS). The Cunningham Panel™ can help identify the level of autoimmune antibodies associated with such neuropsychiatric disorders and the capability they have to stimulate and trigger neurologic behavior.
Lead investor i2E, along with Chicago-based OCA Ventures and Mayo Clinic Ventures, has funded the first round of investment to assist Progentec in moving its technology for predicting the onset of lupus flares closer to commercialization. Technology created by the Oklahoma Medical Research Foundation (OMRF) is at the core of the platform being developed by Progentec.
Stephenson Cancer Center
The Stephenson Cancer Center at the University of Oklahoma was designated as a National Cancer Institute (NCI) Cancer Center. With this award, the Stephenson Cancer Center joins an elite group of 70 NCI-Designated Cancer Centers nationwide. NCI-Designated Cancer Centers represent only the top 2 percent of cancer centers in the United States. Read more at www.velocityokc.com/stephenson.
Oklahoma’s bioscience sector currently contributes more than $6.7 billion in economic activity and supports more than 51,000 Oklahoma jobs. The sector also produces annual revenues of more than $4.1 billion. OKBio represents more than 500 bioscience-related businesses and organizations across the state and is the voice for Oklahoma’s dynamic and diverse bioscience community.